66630-72-6

Basic information

• Product Name: 2-PHENYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID
• Synonyms: 2-PHENYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID;2-Phenyl-1H-benzimidazole-7-carboxylic acid;2-Phenyl-3H-benzimidazole-4-carboxylic acid;2-Phenylbenzimidazole-4-carboxylic acid;2-Phenyl-3H-benzimidazole-4-carboxylic acid, 7-Carboxy-2-phenyl-1H-benzimidazole;2-phenyl-1H-1,3-benzodiazole-7-carboxylic acid
• CAS NO: 66630-72-6
• Molecular Formula: C₁₄H₁₀N₂O₂
• Molecular Weight: 238.24
• Mol File: 66630-72-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 287-288 °C
• Boiling Point: 527.6°C at 760 mmHg
• Flash Point: 272.9°C
• Appearance: /
• Density: 1.377g/cm³
• Vapor Pressure: 5.85E-12mmHg at 25°C
• Refractive Index: 1.717
• PKA: 0.15±0.30(Predicted)
• CAS DataBase Reference: 2-PHENYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PHENYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID(66630-72-6)
• EPA Substance Registry System: 2-PHENYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID(66630-72-6)

Safety Data

• Hazardous Substances Data: 66630-72-6(Hazardous Substances Data)

Usage

General Description

2-PHENYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID is a chemical compound with a molecular structure containing a benzimidazole ring and a carboxylic acid functional group. It is also known as PBI 1402 and is being researched for its potential as a treatment for certain types of anemia, including aplastic anemia and myelodysplastic syndromes. 2-PHENYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID has exhibited hematopoietic stimulating activity and has shown promise as a therapeutic agent for these conditions. Its mechanism of action involves regulating the production of red blood cells and improving bone marrow function. Research continues to explore the potential benefits and applications of 2-PHENYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID in the treatment of anemia and related disorders.

InChI:InChI=1/C14H10N2O2/c17-14(18)10-7-4-8-11-12(10)16-13(15-11)9-5-2-1-3-6-9/h1-8H,(H,15,16)(H,17,18)

Upstream product

• 100-52-7 benzaldehyde 
• 603-81-6 2,3-diaminobenzoic acid 
• 65-85-0 benzoic acid 
• 606-18-8 3-nitroanthranilic acid 
• 77326-45-5 2-carbamoyl-3-nitrobenzoic acid 
• 61063-11-4 2-Amino-3-nitrobenzoic acid,ethyl ester 
• 16533-45-2 ethyl 2-carboxy-3-nitrobenzoate 
• 136285-66-0 3-nitro-phthalic acid-1-ethyl ester-2-chloride 
• 124341-05-5 2-Azidocarbonyl-3-nitro-benzoic acid ethyl ester 
• 201412-02-4 4-ethyl formate-2-phenylbenzimidazole 
• 107582-20-7 2,3-diaminobenzoic acid methyl ester 
• 72470-43-0 2-phenylbenzimidazole-4-carboxylic acid methyl ester 

Downstream Products

• 767234-30-0 2-phenyl-1H-benzoimidazole-4-carbonyl chloride 
• 72470-44-1 NU₁₀₇₀ 
• 250684-05-0 4-(1H-imidazol-1-ylcarobnyl)-2-phenyl-1H-benzimidazole 
• 1446250-90-3 C₂₈H₃₈N₆O₄S 
• 1467592-46-6 4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-phenyl-1H-benzimidazole 

Relevant articles and documents

Synthesis and biological evaluation of novel benzimidazole derivatives bearing a heterocyclic ring at 4/5 position

A series of novel benzimidazole derivatives bearing a heterocyclic ring as oxadiazole (21-32), thiadiazole (33-34), triazole (35-36) were synthesized and evaluated for their activities against Coxsackie virus B3 and B6 in Vero cells. Compounds 21-26, 31-36 with moieties of 2'-pyridyl, 3'-pyridyl and 4'-pyridyl at the 2-position and oxadiazoles, thiadiazole, or triazole substituent at the 4- or 5-position generally displayed activities against CVB3 and CVB6. Especially compound 24 (IC50 = 1.08 μg/mL, SI = 61.7 against CVB3) was the promising candidate as lead compound for anti-enteroviral drug. It was observed in the incorporation of heterocyclic rings in benzimidazole at the 5-position could enhance their biological activities.

Benzimidazole-4-Carboxamide Derivatives, Their Preparation Methods, Pharmaceutical Compositions And Their Uses

The present invention relates to the benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses; wherein X represents monosubstituted or bissubstituted or polysubstitued C1-C14 alkoxy, monosubstituted or bisubstituted or polysubstitued C1-C14 alkyl, monosubstituted or bisubstituted or polysubstitued C2-C14 alkenyl, monosubstituted or bisubstituted or polysubstitued C6-C14 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom; Y represents hydrogen, monosubstituted or bisubstituted or polysubstitued C1-C16 alkyl, monosubstituted or bisubstituted or polysubstitued C6-C12 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom. The derivatives of the present invention have the functions of antiviral medicine.

Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof

The present invention provides an efficient and versatile method for the synthesis and screening of combinatorial libraries of benzimidazoles, benzoxazoles, benzothiazoles, and derivatives thereof. In order to expedite the synthesis of large arrays of compounds possessing these core structures, a general methodology for solid phase synthesis of these derivatives is provided. Arrays of benzimidazoles, benzoxazoles, benzothiazoles, and derivatives thereof useful as peptidomimetics and for the identification of agents having antifungal, antiviral, antimicrobial, anticoagulant, and antiulcer activity, or use in the treatment of inflammation, hypertension, cancer, and other conditions can be prepared by this method.